Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on FLT3, RET, and RAF-MEK1/2 related tumor models.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Targeted Oncology
(1)  FLT3 background
  • FLT3 biology
  • Summary of FLT3 inhibitors

(2)  FLT3-related CDX models
  • MV4-11 leukemia CDX model, validated with Sunitinib, Quizartinib, and TAK-659

(3)  FLT3-ITD engineered cell lines
  • Ba/F3-FLT3-ITD, Ba/F3-FLT3-ITD-F691L and Ba/F3-FLT3-ITD-D835Y cell lines, validated with Ponatinib, Sunitinib, and Sorafenib in vitro
  • Newly established MV4-11 cell line overexpressing FLT3-ITD-F691L or FLT3-ITD-D835Y

(1)  RET background
  • RET biology
  • Summary of RET inhibitors

(2)  RET-related CDX models
  • TT thyroid and LC-2/ad lung cancer CDX models

(3)  RET engineered cell lines
  • Ba/F3-KIF5B-RET-WT, Ba/F3-KIF5B-RET-V804L and Ba/F3-KIF5B-RET-V804M cell lines, validated with Ponatinib, Sunitinib and Sorafenib in vitro
  • Ba/F3-CCDC6-RET-WT, Ba/F3-CCDC6-RET-V804M and Ba/F3-CCDC6-RET-V804L cell lines, validated with Cabozantinib, Vandetanib, Lenvatinib, Sunitinib, Regorafenib and Pralsetinib in vitro
  • Newly established Ba/F3-KIF5B-RET-G810R and Ba/F3-KIF5B-RET-G810S cell lines

(1)  RAF-MEK1/2 background
  • RAF-MEK1/2 pathway biology
  • Summary of RAF or MEK1/2 inhibitors

(2)  RAF-MEK1/2 related CDX models
  • HT29 colon cancer, A375 melanoma, A549 and NCI-H358 lung cancer CDX models, validated with Trametinib
  • COLO 829 melanoma and DU4475 breast cancer CDX models, validated with Dabrafenib
  • COLO 205 colon cancer and SK-MEL-28 melanoma CDX models, carrying BRAF V600E mutation

(3)  RAF-MEK1/2 related PDX models
  • 7 PDX models covering melanoma, pancreatic cancer and colon cancer, carrying BRAF V600E mutation
  • ME-21-0001 melanoma PDX model, validated with Dabrafenib

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,
WuXi AppTec OncoWuXi Team